Evidence map›Paper›PMID 35062796›Full record

ArticleVaccines2022

COVID-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran.

Seyed Massood Nabavi, Mehrnoosh Mehrabani, Leila Ghalichi, Mohammad Ali Nahayati, Mehran Ghaffari, Fereshteh Ashtari, Seyed Ehsan Mohammadianinejad, Shahedeh Karimi, Leila Faghani, Sepideh Yazdanbakhsh and 3 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Seyed Massood NabaviArya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran.
Mehrnoosh MehrabaniArya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran.
Leila GhalichiArya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran.
Mohammad Ali NahayatiNeurology Department, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran.
Mehran GhaffariNeurology Department, Shahid Beheshti University of Medical Sciences, Tehran 1983969411, Iran.
Fereshteh AshtariNeurology Department, Isfahan University of Medical Sciences, Isfahan 73461-81746, Iran.
Seyed Ehsan MohammadianinejadNeurology Department, Jondishapour University of Medical Sciences, Ahvaz 15794-61357, Iran.
Shahedeh KarimiArya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran.
Leila FaghaniArya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran.
Sepideh YazdanbakhshArya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran.
Abbas NajafianArya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran.
Koorosh ShahpasandDepartment of Brain and Cognitive Sciences, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Tehran 1665659911, Iran.
Massoud VosoughArya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran.ORCID 0000-0001-5924-4366
Royan Institute · IRAhvaz Jundishapur University of Medical Sciences · IRIran University of Medical Sciences · IRIsfahan University of Medical Sciences · IRMashhad University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic, predominantly immune-mediated degenerative disease of the central nervous system. Due to prolonged use of immunomodulatory and immunosuppressive medications, vaccine hesitancy could be common among MS patients. Our main aim in the current study was to evaluate the willingness and acceptability of COVID-19 vaccination in patients with MS. In our multicenter cross-sectional questionnaire-based clinical study, 892 patients completed the questionnaire between May to June 2021. The questionnaire consisted of demographic data, MS disease-related factors, history of COVID-19 infection/vaccination, and any existing comorbidities. Statistical analysis was performed using SPSS software version 19. Overall, 68% of the participants expressed willingness to be vaccinated. Major causes of vaccine refusal in our patients were the fear of reducing the efficacy of disease modifying drugs (DMDs) upon vaccination as well as distrusting the vaccines and overestimation bias in the power of their innate immunity and potential COVID-19 resistance. Some demographic factors affected vaccination enthusiasm in our study. Our findings did not show significant correlation between the age and comorbidity and vaccine willingness. Only one-third of our patients received their vaccine information from healthcare providers. The majority of them received these data from official broadcasting channels and social media. However, despite several concerns, the willingness of COVD-19 vaccination in the Iranian MS patients is remarkable.

Indexed as

COVID-19 vaccinationmultiple sclerosisvaccine acceptabilityvaccine hesitancyvaccine willingness

Identifiers

PMID35062796
PMCPMC8778456
OpenAlexW4206181704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.